|Mr. Utpal Koppikar||Sr. VP & CFO||430.46k||N/A||1970|
|Mr. Joseph Newell||Exec. VP & Chief Technical Operations Officer||536.58k||292.72k||1970|
|Ms. Mina Kim||Consultant||457.91k||N/A||1974|
|Dr. Pascal Touchon||Pres, CEO & Director||N/A||N/A||1964|
|Dr. John Craighead||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Atara Biotherapeutics, Inc.’s ISS governance QualityScore as of 3 December 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 7; Compensation: 9.